Vor Biopharma Inc. - Common Stock (VOR)

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy.

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints.

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing.

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.